Stockscreener 앱 받기
257.25
2.76%
-7.29
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up - Yahoo Finance
Praxis Precision Medicines shareholders elect directors and approve proposals at annual meeting - Investing.com India
Praxis Precision Medicines (PRAX) director receives RSU and option grants - Stock Titan
Praxis Precision Medicines (PRAX) director granted RSUs and options as equity pay - Stock Titan
Praxis (NASDAQ: PRAX) director William Young receives RSU and option grants - Stock Titan
Praxis (PRAX) director Jill DeSimone granted 1,371 RSUs and 648 options - Stock Titan
Praxis (PRAX) director awarded 1,371 RSUs and 648-share stock option - Stock Titan
Praxis (PRAX) director J. Dean Mitchell granted RSUs and stock options - Stock Titan
Praxis (PRAX) director Kindler awarded RSUs and stock options as compensation - Stock Titan
Praxis Precision Medicines (PRAX) director granted RSUs and stock options - Stock Titan
Praxis Precision Medicines (PRAX) shareholders approve board, auditor and say-on-pay - Stock Titan
PRAX Stock Quote Price and Forecast - CNN
BTIG Reaffirms Buy Rating for Praxis Precision Medicines (PRAX) - Insider Monkey
Praxis Submits NDAs for Ulixacaltamide in Essential Tremor and Relutrigine in SCN2A/SCN8A Developmental Epileptic Encephalopathies - NeurologyLive
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
PRAX: All proposals, including director elections and auditor ratification, were approved by shareholders - TradingView
Praxis Precision Medicines Inc Annual Shareholders Meeting Transcript - GuruFocus
BTIG maintains Praxis Precision Medicines (PRAX) buy recommendation - MSN
Praxis Precision Medicines Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Transcript : Praxis Precision Medicines, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08 - marketscreener.com
Technical Reactions to PRAX Trends in Macro Strategies - Stock Traders Daily
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - Moomoo
Praxis down on trial setback for seizure therapy - MSN
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor (PRAX) - Seeking Alpha
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings - Insider Monkey
5 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds - Insider Monkey
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference - Investing News Network
Wedbush Analyst Ratings On PRAX, IDYA, EWTX, JADE - RTTNews
Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX) - The Globe and Mail
TD Cowen Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines Faces Vormatrigine Setback And Reassesses Epilepsy Pipeline - Yahoo Finance
PRAX Maintained by Oppenheimer -- Price Target Lowered to $650 - GuruFocus
PRAX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
PRAX Maintains Outperform by Baird -- Price Target Lowered to $4 - GuruFocus
The Shocking Twist That Sent This Seizure-Focused Biotech Into A Dive - Investor's Business Daily
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Biopharmaceutical Praxis gives new hires stock units vesting over 4 years - Stock Titan
Praxis Precision (PRAX) Sees Major Decline in Stock Value - GuruFocus
H.C. Wainwright cuts Praxis Precision Medicines stock price target on trial miss - Investing.com UK
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss - Investing.com UK
PRAX Maintained by Deutsche Bank -- Price Target Lowered to $374 - GuruFocus
PRAX Maintained by Wedbush -- Price Target Lowered to $162 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure - Investing.com UK
Praxis Precision Medicines slides after vormatrigine POWER1 trial misses primary endpoint - Quiver Quantitative
Oppenheimer Adjusts Praxis Precision Medicines PT to $650 From $750, Maintains Outperform Rating - Moomoo
Praxis Precision Medicines (PRAX) Phase 2/3 Study Fails to Meet Primary Endpoint - GuruFocus
PRAX Maintained by BTIG -- Price Target Lowered to $810 - GuruFocus
Truist cuts Praxis Precision Medicines stock price target on trial failure By Investing.com - Investing.com Australia
TD Cowen cuts Praxis Precision Medicines stock price target to $550 on trial miss By Investing.com - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Compass Therapeutics (CMPX) and Tenax Therapeutics (TENX) - The Globe and Mail
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $162 to $1,201 - Moomoo
1.27%
1.43%
자본화:
|
볼륨(24시간):